Next Phase Newsletter

A registered investment consultancy firm is involved with independent advisory, outsourced CIO, and direct investments. The firm acts as the consultant role to advise global family offices with their investment objectives. The firm is looking for investment leads in early-stage life science industry. Companies who are looking to raise their series B – series C rounds would be in their sweet spot. The firm typically invests in $1M-25M, which depends on the stage of development.

The firm is also open to looking at earlier stage companies but the investment size might vary. The firm is looking for companies in the US (60%), China (20%), UK, Germany, India, and other countries with emerging life science technologies.

The firm is opportunistic in sectors and is willing to consider any indications.

The firm has no specific requirements for companies. The firm might take an observer seat or board seat in applicable cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A PE firm based in China manages 2 active funds – the RMB and USD Funds – that focus on investments in the life science space. The RMB Fund invests $5-40 M in companies based in China, and the USD Fund invests $5-10 M in companies of all parts of the world, with a focus in US and China. With these funds, the firm will make 1-2 investments per year in companies that have market opportunities in China. The firm will provide companies with resources and expertise for competitive market entry and will assist pre-market products with commercialization.

The firm is opportunistic and is open to all life science sectors in all indications, including therapeutics, medical technology, diagnostics, and digital health. In therapeutics, the firm will consider products that are in Phase II clinical trials and beyond, but may consider companies with pre-clinical or early clinical assets if they demonstrate high potential. In the medical technology sector, the firm will support devices of all regulatory pathways and will also assist with CFDA regulatory filing and approval. These devices are expected to be undergoing pivotal trials at the earliest, and should be close to commercialization.

The firm will invest only in companies that are looking to enter the market in China, and is willing to both lead and co-invest. The companies will ideally have an IPO or trade sale runway of 6 to 24 months. Companies should be backed by an experienced management team but for companies based in China, the firm can assist with the assembly of a complete management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office behind a large industrial engineering firm invests in and incubates new technologies in the medical device and consumer health sectors. The firm is invests directly into early stage companies, focusing on opportunities in which the firm’s engineering and commercialization expertise can provide a value-add. The firm’s investments may include equity financing, services such as prototyping and design, and other structures such as royalties. The firm invests worldwide.

The firm focuses on medical technology and consumer health, including devices, diagnostics, sterilization, blood testing, sensors, MRI/Radiation machines, and home health products. The firm is a multi-stage investor, and has worked with entrepreneurs as early as idea-stage. The firm invests in all classes of medical device including PMA opportunities. Hardware only.  No pure software, biotech/drugs/medication or services businesses.

The firm is focused on investing in companies in which the firm’s expertise is a relevant value-add.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A healthcare-focused venture capital firm linked to a large provider of preventative and diagnostic services currently has a $50M seed stage fund through which they invest mainly in Seed to Series A companies across all geographies. Despite the fund’s affiliation with this large company, the firms are separate entities and as an institutional venture capital firm, financial return is an important factor. However, because of this affiliation, the firm is able to leverage corporate benefits to support the growing needs of their portfolio companies. As of March 2021, the firm has invested in 6 EMEA companies and 8 USA companies. Initial sizes of investment can largely vary, from $250K to 4M and a portion of the fund is reserved for follow-on investment.

Traditionally, the firm has been most interested in healthcare IT and services companies that address important problems in the healthcare industry, including reducing healthcare costs and improving patient outcomes. However, the firm has been pushing beyond healthtech and pursuing investments in the fields of diagnostics, genomics, and medtech. The firm is not interested in biotech.

The firm is able to leverage their relationship with its parent company to provide hands-on support for their portfolio companies. The firm is open to both leading and co-investing and has done both. The firm is more likely to lead and seek board representation for companies that are based in proximity with the firm’s team. The firm does not have specific requirements for the company or management team as long as they have compelling technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Founded in 2020 and based in California, a life science venture capital is interested in therapeutic, medical device, diagnostic, and digital health technologies. The firm usually participates in Seed to series C financing rounds with check sizes between $500K – 2M USD. The firm is open to both leading and co-investing and is aiming to make 15 investments in the next 12 months. The firm is open to global opportunities.

The firm is open to considering innovative technologies that address unmet medical needs in therapeutics, diagnostics, medical devices, and digital health. The firm’s greatest interest lies in the biotech and diagnostic sector in which the firm has the strongest expertise. For medical devices and diagnostics, the firm is open to any subsectors but is most interested in AI-based diagnostics and innovative genomics applications. The firm is open to any indication area including oncology, CNS diseases and rare diseases.

The firm seeks to work with companies with a sound business model and great execution, but will mainly focus on the merit of technologies and the team when working with very early-stage companies. The firm considers itself to be an active investor and will take a board seat depending on the cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

An investment firm founded by a group of Chinese medical device experts based in China. The firm seeks to allocate 5-20M RMB (0.7-3M USD) in various early-stage life science opportunities. The firm is looking to make several investments in the upcoming year focusing on angel, pre-A, Series A, and B rounds. The firm seeks to make use of the founders’ expertise in the medical device industry to help guide their investments towards growth and success. The firm is investing out of a CNY fund and therefore focuses on companies willing to start a joint venture in China.

The firm is primarily interested in medical devices and in vitro diagnostic (IVD) technologies. The firm’s greatest interest lies in cardiology, neuromodulation, in-vitro diagnostics, and imaging, where the founders have the most expertise. The firm is open to considering other areas, including R&D services, as long as the opportunity is interesting and has the potential to be developed. The firm’s most recent investment was in a company that utilized AI to process images in order for better and faster diagnoses.

The firm strongly prefers companies with China angle. The firm believes that they can contribute more to companies who wish to work in China through their established connections. The firm also prefers to work with companies that are open to collaborating with the firm’s partners so that they can utilize their prior experiences to help the companies grow.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Established in 2014, the venture arm of a large pharmaceutical company focuses on novel therapeutics R&D. The firm is seeking for the partnership in new technique platforms, new targets in the therapeutic areas of oncology, IO, neuroscience, diabetes and other areas with unmet medical needs. The firm is also interested in AI for drug discovery and development.

The firm is especially interested in Antibody therapeutics including new structure antibodies, Gene Therapy, Car-T, Targeted Therapy, oncolytic virus therapy, and rare disease.

The firm has no specific requirements for the company and management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.